Sutro Biopharma, Inc.
STRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $3 | $4 | $7 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $3 | $4 | $7 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -59.6% | 126.8% | 9.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 88.4% | 95.6% | 87.8% | 84.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -290.9% | -44.2% | -155% | -157.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -366.6% | -69.5% | -175.9% | -170.6% |
| EPS Diluted | -29.6 | -17.8 | -23.5 | -22.9 |
| % Growth | -66.3% | 24.3% | -2.6% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |